AstraZeneca PLC (AZNCF)
| Previous Close | 133.95 |
| Open | 137.93 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 137.93 - 137.93 |
| 52 Week Range | 104.50 - 153.10 |
| Volume | |
| Avg. Volume | 2,258 |
| Market Cap | 216.567B |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | 34.92 |
| EPS (TTM) | 3.95 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.89 (2.16%) |
| Ex-Dividend Date | Aug 10, 2023 |
| 1y Target Est | N/A |
- Reuters
EXPLAINER-What you need to know about RSV and the new vaccines
Expert advisers to U.S. Centers for Disease Control and Prevention (CDC) on Friday recommended Pfizer's respiratory syncytial virus (RSV) vaccine for women in the middle of the third trimester of pregnancy to protect their babies from severe illness. That Pfizer shot and one developed by GSK in May became the first two RSV vaccines to win U.S. approval, for use in people aged 60 and over to prevent severe illness.
Business WireDatopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
WILMINGTON, Del., September 22, 2023--Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival (PFS) compared to investigator’s choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated wit
ZacksAstrazeneca (AZN) Stock Moves -1.38%: What You Should Know
Astrazeneca (AZN) closed at $67.02 in the latest trading session, marking a -1.38% move from the prior day.
